<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03224598</url>
  </required_header>
  <id_info>
    <org_study_id>A-101-DPN-201</org_study_id>
    <nct_id>NCT03224598</nct_id>
  </id_info>
  <brief_title>A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra</brief_title>
  <official_title>A Phase 2 Open Label Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aclaris Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aclaris Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety and efficacy of hydrogen peroxide, A-101 Solution 40% for the treatment
      of DPN lesions on subjects with a Fitzpatrick Skin Type of 5 or 6.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to evaluate the safety and efficacy of hydrogen peroxide,
      A-101 Solution 40% for the treatment of DPN lesions on subjects with a Fitzpatrick Skin Type
      of 5 or 6.

      The secondary objectives of this study include:

        -  Durability of response

        -  Safety

      An exploratory objective of this study will evaluate the subject's assessment of the
      treatment of A-101 to DPN lesions using a Subject Self-Assessment Scale.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 26, 2017</start_date>
  <completion_date type="Actual">January 8, 2019</completion_date>
  <primary_completion_date type="Actual">January 8, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The first cohort of the study will enroll a total of 12 subjects. In the second part of the study, subjects will be a randomized to additional two-arm cohorts. Subjects will be randomized to one of the following 2 treatment arms:
A-101 40% without medically abrading the identified DPN prior to treatment
A-101 40% with the identified DPN lesions medically abraded prior to treatment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physician's DPN Lesions Assessment</measure>
    <time_frame>Day 106</time_frame>
    <description>Efficacy endpoints will include summary statistics (frequency distributions, proportions, means, medians and standard deviations, as appropriate) by visit for the following parameters: Physician's DPN Lesion Assessment scale results per treated lesion, subject responders defined by Physician's DPN Lesion Assessment scale outcome, and changes from baseline treated lesion diameter
Physician's DPN Lesion Assessment Grade Descriptor 0 Clear: no visible DPN lesion;
Near Clear: a slightly visible DPN lesion; lesion may be macular
Small: a visible DPN lesion with a diameter of less than 3 mm
Large : a visible DPN lesion that is elevated with a diameter of ≥3 mm</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Dermatosis Papulosa Nigra</condition>
  <arm_group>
    <arm_group_label>No medical abrading</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A-101 40% without medically abrading the identified DPN prior to treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medically abrading</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A-101 40% with the identified DPN lesions medically abraded prior to treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Initial cohort - no medical abrading</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A-101 40% without medically abrading the identified DPN prior to treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A-101 Topical Solution 40%</intervention_name>
    <description>A-101 Topical Solution 40%</description>
    <arm_group_label>Initial cohort - no medical abrading</arm_group_label>
    <arm_group_label>Medically abrading</arm_group_label>
    <arm_group_label>No medical abrading</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provisions of written informed consent for participation in this study.

          2. Male or female ≥ 18 years old.

          3. Subject has a clinical diagnosis of dermatosis papulose nigra.

          4. Fitzpatrick Skin Type of 5 or 6

          5. Subject has 4 target DPN lesions located in an area that has not been previously
             treated.

          6. Subject chemistry and complete blood count results are within normal limits for the
             central laboratory.

          7. Woman of childbearing potential must have a negative urine pregnancy test within 14
             days of the first application of study drug and agree to use an active method of birth
             control for the duration of the study

          8. Subject is non-pregnant and non-lactating.

          9. Subject is in good general health and free of any known disease state or physical
             condition.

         10. Subject is willing and able to follow all study instructions and to attend all study
             visits.

        Exclusion Criteria:

          1. Subject has clinically atypical and /or rapidly growing DPN lesion.

          2. Subject has current systemic malignancy.

          3. Subject has a history of keloids

          4. Subject has a history of post inflammatory hyperpigmentation lasting longer than 1
             year.

          5. Subject has used any of the following systemic therapies within the specified period
             prior to Visit 1:

               -  Retinoids; 180 days

               -  Corticosteroids; 28 days

               -  Antimetabolites (e.g., methotrexate); 28 days

          6. Subject has used any of the following topical therapies within the specified period
             prior to Visit 1 on, or in a proximity to any Target Lesion, that in the
             investigator's opinion interferes with the study medication treatment or the study
             assessments:

               -  LASER, light or other energy based therapy (e.g., intense pulsed light [IPL],
                  photo-dynamic therapy [PDT]; 180 days

               -  Liquid nitrogen, electrodesiccation, curettage, imiquimod, 5-fluoruracil (5FU),
                  or ingenol mebutate; 60 days

               -  Retinoids; 28 days

               -  Microdermabrasion or superficial chemical peels; 14 days

               -  Corticosteroids or antibiotics; 14 days.

          7. Subject currently has or has had any of the following within the specified period
             prior to Visit 1 on or in a proximity to any Target Lesion that, in the investigator's
             opinion, interferes with the study medication treatment or the study assessments:

               -  Cutaneous malignancy; 180 days

               -  Sunburn; currently

               -  Pre-malignancy (e.g. actinic keratosis); currently

               -  Body art (e.g. tattoos, piercing, etc.); currently

               -  Excessive tan. The use of self-tanning lotions/sprays are prohibited.

          8. Subject has a history of sensitivity to any of the ingredients in the study
             medications.

          9. Subject has any current skin disease (e.g. psoriasis, atopic dermatitis, eczema, sun
             damage), or condition (e.g. sunburn, excessive hair, open wounds) that, in the opinion
             of the investigator, might put the subject at undue risk by study participation or
             interfere with the study conduct or evaluations.

         10. Participation in another therapeutic investigational drug trial in which
             administration of an investigational study medication occurred with 30 days prior to
             Visit 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Aclaris Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aclaris Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 5, 2017</study_first_submitted>
  <study_first_submitted_qc>July 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <results_first_submitted>January 14, 2020</results_first_submitted>
  <results_first_submitted_qc>January 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 10, 2020</results_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Diseases</mesh_term>
    <mesh_term>Skin Diseases, Papulosquamous</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT03224598/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 19, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT03224598/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>No Medical Abrading</title>
          <description>A-101 40% without medically abrading the identified DPN prior to treatment
A-101 Topical Solution 40%: A-101 Topical Solution 40%</description>
        </group>
        <group group_id="P2">
          <title>Medically Abrading</title>
          <description>A-101 40% with the identified DPN lesions medically abraded prior to treatment
A-101 Topical Solution 40%: A-101 Topical Solution 40%</description>
        </group>
        <group group_id="P3">
          <title>Initial Cohort - no Medical Abrading</title>
          <description>initial cohort no medical abrading different treatment schedule</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>No Medical Abrading</title>
          <description>A-101 40% without medically abrading the identified DPN prior to treatment
A-101 Topical Solution 40%: A-101 Topical Solution 40%</description>
        </group>
        <group group_id="B2">
          <title>Medically Abrading</title>
          <description>A-101 40% with the identified DPN lesions medically abraded prior to treatment
A-101 Topical Solution 40%: A-101 Topical Solution 40%</description>
        </group>
        <group group_id="B3">
          <title>Initial Cohort - no Medical Abrading</title>
          <description>A-101 40% without medically abrading the identified DPN prior to treatment
A-101 Topical Solution 40%: A-101 Topical Solution 40%
initial cohort no medical abrading different treatment schedule</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="13"/>
            <count group_id="B4" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fitzpatrick Skin Type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>fitzpatrick 5: Rarely burns, tans darkly easily</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>fitzpatrick 6: Never burns, always tans darkly</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Physician's DPN Lesions Assessment</title>
        <description>Efficacy endpoints will include summary statistics (frequency distributions, proportions, means, medians and standard deviations, as appropriate) by visit for the following parameters: Physician's DPN Lesion Assessment scale results per treated lesion, subject responders defined by Physician's DPN Lesion Assessment scale outcome, and changes from baseline treated lesion diameter
Physician's DPN Lesion Assessment Grade Descriptor 0 Clear: no visible DPN lesion;
Near Clear: a slightly visible DPN lesion; lesion may be macular
Small: a visible DPN lesion with a diameter of less than 3 mm
Large : a visible DPN lesion that is elevated with a diameter of ≥3 mm</description>
        <time_frame>Day 106</time_frame>
        <population>per-protocol</population>
        <group_list>
          <group group_id="O1">
            <title>No Medical Abrading</title>
            <description>A-101 40% without medically abrading the identified DPN prior to treatment
A-101 Topical Solution 40%: A-101 Topical Solution 40%</description>
          </group>
          <group group_id="O2">
            <title>Medically Abrading</title>
            <description>A-101 40% with the identified DPN lesions medically abraded prior to treatment
A-101 Topical Solution 40%: A-101 Topical Solution 40%</description>
          </group>
          <group group_id="O3">
            <title>Initial Cohort - no Medical Abrading</title>
            <description>initial cohort no medical abrading different treatment schedule</description>
          </group>
        </group_list>
        <measure>
          <title>Physician's DPN Lesions Assessment</title>
          <description>Efficacy endpoints will include summary statistics (frequency distributions, proportions, means, medians and standard deviations, as appropriate) by visit for the following parameters: Physician's DPN Lesion Assessment scale results per treated lesion, subject responders defined by Physician's DPN Lesion Assessment scale outcome, and changes from baseline treated lesion diameter
Physician's DPN Lesion Assessment Grade Descriptor 0 Clear: no visible DPN lesion;
Near Clear: a slightly visible DPN lesion; lesion may be macular
Small: a visible DPN lesion with a diameter of less than 3 mm
Large : a visible DPN lesion that is elevated with a diameter of ≥3 mm</description>
          <population>per-protocol</population>
          <units>score on a scale (PLA)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="0.52"/>
                    <measurement group_id="O2" value="-1.38" spread="0.90"/>
                    <measurement group_id="O3" value="-0.92" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>106 days</time_frame>
      <desc>An adverse event (AE) is any untoward medical occurrence in a patient that develops or worsens in severity during the conduct of a clinical study of a pharmaceutical product and does not necessarily have a causal relationship to the study drug.
assessed at all visits</desc>
      <group_list>
        <group group_id="E1">
          <title>No Medical Abrading</title>
          <description>A-101 40% without medically abrading the identified DPN prior to treatment
A-101 Topical Solution 40%: A-101 Topical Solution 40%</description>
        </group>
        <group group_id="E2">
          <title>Medically Abrading</title>
          <description>A-101 40% with the identified DPN lesions medically abraded prior to treatment
A-101 Topical Solution 40%: A-101 Topical Solution 40%</description>
        </group>
        <group group_id="E3">
          <title>Initial Cohort - no Medical Abrading</title>
          <description>initial cohort no medical abrading different treatment schedule</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (21.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>eye pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash vesicular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Executive Director Clinical Operations</name_or_title>
      <organization>Aclaris Therapeutics</organization>
      <phone>4843247933</phone>
      <email>jschnyder@aclaristx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

